Home / Health / FDA Approves Foundayo, a New Oral Weight-Loss Medication
FDA Approves Foundayo, a New Oral Weight-Loss Medication
1 Apr
Summary
- FDA approved Foundayo, Eli Lilly's new daily weight-loss pill.
- Foundayo achieved about 12% average weight loss in trials.
- The pill offers a convenient alternative to injectable weight-loss drugs.
The U.S. Food and Drug Administration (FDA) has approved Foundayo, a new daily oral medication for weight loss developed by Eli Lilly. This approval introduces a significant new option for individuals managing obesity, offering a more convenient alternative to existing injectable treatments.
Clinical trials demonstrated Foundayo's efficacy, with participants losing an average of around 12 percent of their body weight after 72 weeks of using the highest dosage. The pill functions by mimicking a natural hormone that helps control appetite and regulate blood sugar levels.
Foundayo is positioned as a more accessible option, as it can be taken at any time, with or without food, unlike some other weight-loss medications that require specific timing and an empty stomach. Eli Lilly also plans to seek FDA approval for Foundayo for diabetes treatment later this year.
Patients may experience gastrointestinal side effects similar to those of injectable weight-loss drugs, such as nausea and diarrhea. The availability of Foundayo allows for more personalized discussions between patients and doctors regarding the best weight-loss strategy based on convenience, side effects, and cost.
